Additional Information

Description

Ocrevus (ocrelizumab) 30 mg/mL, 10 mL single-dose vial is a monoclonal antibody used in the treatment of multiple sclerosis (MS). It targets and depletes CD20-positive B cells, which are believed to play a critical role in the pathophysiology of MS by contributing to immune system attacks on the nervous system.

This medication is administered intravenously and is typically given as an infusion in a healthcare setting. The dosing schedule for Ocrevus generally involves an initial dose, followed by subsequent doses every six months. The treatment is administered slowly to minimize the risk of infusion-related reactions, such as fever, chills, or difficulty breathing.

Common side effects include respiratory infections, headache, and infusion reactions. Serious side effects can include an increased risk of infections, particularly respiratory infections, and potential development of malignancies. Regular monitoring for infections, liver function, and infusion-related reactions is advised during treatment.